Abstract 1495P
Background
Socially isolated patients have a higher early mortality rate across multiple cancers. However, there have been no reports on how social isolation such as solitary life affects the clinical outcomes in advanced non-small cell lung cancer (NSCLC).
Methods
We conducted a retrospective analysis of patients with advanced NSCLC who received systemic therapy at the National Cancer Center (NCC) between January 2021 and December 2023. This study assessed the association between social isolation, such as living alone, and clinical outcomes, including overall survival (OS) and the incidence of serious adverse events (SAE) during systemic treatment. Additionally, we evaluated the transition rates to palliative care, both at home and in palliative care units (PCU), as well as the proportion of in-hospital deaths at our institution.
Results
During the study period, 679 patients initiated systemic treatment for advanced NSCLC. Of these, 119 patients were living alone (alone group) while the remaining 560 were not (non-alone group). The median age was comparable between the alone and non-alone groups (63 vs. 67 years, p=0.20), but the alone group had a higher proportion of females (46.2% vs. 37.5%, p=0.08). Regarding the driver genetic alterations, there was no significant difference between the two groups in the presence of EGFR mutations (36.1% vs. 32.1%, p=0.70) and ALK rearrangement (7.4% vs. 5.3%, p=0.66). Treatment modalities were also comparable between the alone group and non-alone groups for TKI use (44.1% vs. 39.5%, p=0.86). The alone group showed numerically better outcomes in OS and SAE rates than the non-alone group (OS: not reached vs. 50.7 months, p=0.11; and SAE: 10.9% vs. 18.8%, p=0.08). In the alone group, the transition rates to palliative care at home was significantly lower (13.0% vs. 32.0%, p=0.04), and the proportion of in-hospital deaths (NCC or PCU) was higher compared with non-alone group (82.6% vs. 66.7%, p=0.04).
Conclusions
Social isolation such as living alone did not affect the clinical outcomes such as OS and SAE during the systemic treatment in advanced NSCLC patients. However, it did influence the palliative care practices, resulting in a higher rate of hospital deaths.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
T.Yoshida.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1594P - Cancer mortality in young population and estimated radon areas in Spain
Presenter: Miquel Ferriol-Galmés
Session: Poster session 10
1598P - Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study
Presenter: William Kelly
Session: Poster session 10
1600P - Phase II trial of pembrolizumab and lenvatinib in advanced neuroendocrine prostate cancer (NEPC)
Presenter: Ulka Vaishampayan
Session: Poster session 10
1601P - First results from ZZFIRST: A randomized phase II trial of enzalutamide (EZ) with or without talazoparib (TALA) in metastatic hormone-naïve prostate cancer (mHNPC)
Presenter: Joaquin Mateo
Session: Poster session 10
1602P - CBP-1018, Bi-ligand-drug conjugate (Bi-XDC) drug treated for metastatic castration resistant prostate cancer (mCRPC) patients from phase I study results
Presenter: Kaiwen Li
Session: Poster session 10
1603P - Updated safety and efficacy of tazemetostat (TAZ) plus enzalutamide (ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Wassim Abida
Session: Poster session 10
1604P - PSMA-targeted radioligand therapy (RLT) with 131I-LNTH-1095 (1095) plus enzalutamide (enza) vs enza alone in chemotherapy-naïve patients (pts) whose piflufolastat F 18-avid metastatic castration-resistant prostate cancer (mCRPC) progressed on abiraterone (abi): ARROW
Presenter: Evan Yu
Session: Poster session 10
1605P - Opevesostat (MK-5684/ODM-208), an oral CYP11A1 inhibitor, in metastatic castration-resistant prostate cancer (mCRPC): Updated CYPIDES phase II results
Presenter: Karim Fizazi
Session: Poster session 10
1606P - Mature follow up of phase I dose finding trial of pembrolizumab (pembro) with AR inhibitors (ARI) and priming tumour-targeted radiation with anti-PSMA alpha emitter 225Ac-J591
Presenter: Aaron Holmes
Session: Poster session 10